Objective-Staphylococcus aureus can induce platelet aggregation. The rapidity and degree of this correlates with the severity of disseminated intravascular coagulation, and depends on platelet peptidoglycans. Surface-located thiol isomerases play an important role in platelet activation. The staphylococcal extracellular adherence protein (Eap) functions as an adhesin for host plasma proteins. Therefore we tested the effect of Eap on platelets. Methods and Results-We found a strong stimulation of the platelet-surface thiol isomerases protein disulfide isomerase and endoplasmic reticulum stress proteins 57 and 72 by Eap. Eap induced thiol isomerase-dependent glycoprotein IIb/ IIIa activation, granule secretion, and platelet aggregation. Treatment of platelets with thiol blockers, bacitracin, and anti-protein disulfide isomerase antibody inhibited Eap-induced platelet activation. The effect of Eap on platelets and protein disulfide isomerase activity was completely blocked by glycosaminoglycans. Inhibition by the hydrophobic probe bis(1-anilinonaphthalene 8-sulfonate) suggested the involvement of hydrophobic sites in protein disulfide isomerase and platelet activation by Eap. Conclusion-In the present study, we found an additional and yet unknown mechanism of platelet activation by a bacterial adhesin, involving stimulation of thiol isomerases. The thiol isomerase stimulatory and prothrombotic features of a microbial secreted protein are probably not restricted to S aureus and Eap. Because many microorganisms are coated with amyloidogenic proteins, it is likely that the observed mechanism is a more general one. 
B
acteremic infections can be a cause of serious vascular complications, such as infective endocarditis (IE), 1 disseminated intravascular coagulation, 2 and thrombocytopenia. 3 In addition, there is strong evidence for the contribution of infection to arteriosclerosis, 4 ,5 myocardial infarction, 6 and stroke. 7, 8 Although a wide range of bacteria can cause IE, the majority of cases can be attributed to Staphylococcus aureus. 9 The reason for this dominance is not known. Infections with S aureus are also associated with an increased risk of myocardial infarction 10 and stroke, 11 conditions which are characterized by exaggerated platelet function. Several surface-located proteins of S aureus have been demonstrated to activate and aggregate platelets, including the fibrinogen (Fg)-binding clumping factors ClfA and ClfB, and the fibronectin-binding proteins FnBPA and FnBPB. [12] [13] [14] Besides these surface-bound adhesins, S aureus also secretes adhesive proteins, such as the extracellular Fg-binding protein, coagulase, the extracellular matrix-binding protein, and the extracellular adherence protein (Eap). 15 
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The virulence factor Eap is specifically restricted to S aureus, and was found in all isolates tested so far. 16 With some strain-specific variations, Eap consists of 4 to 6 tandem repeat (EAP) domains. 17 By the formation of oligomers, Eap is able to agglutinate S aureus. 18 The multirepeat protein shows a broad binding spectrum to matrix and plasma proteins, including Fg, fibronectin, vitronectin, prothrombin, laminin, elastin, several types of collagen, and thrombospondin-1 (TSP-1). [18] [19] [20] Eap promotes the adherence of S aureus to both fibroblasts and epithelial cells, 18, 21 as well as the adhesion to and internalization by endothelial cells. 22 In several recent studies, Eap has been found to be an immunomodulating agent. It binds to intracellular adhesion molecule 1, inhibits the adhesion of leukocytes to endothelial cells, and subsequently the transendothelial migration of leukocytes. 22 On the other hand, Eap is associated with an impaired wound healing in mice, 23 and induces the secretion of the proinflammatory cytokines interleukin-6 and tumor necrosis factor- by monocytes and macrophages. This effect is inhibited by an antibody against intracellular adhesion molecule 1, indicating that Eap plays a role in cellular activation. 24 In addition, Massey et al 25 observed an enhancement of major histocompatibility complex molecule binding to human leukocytes. The effect of Eap on proliferation of peripheral blood mononuclear cells is ambiguous. Low concentrations (up to 9 g/mL) induce a proliferative response whereas high concentrations inhibit T-cell proliferation and induce cell death. 26 In the present study, we demonstrate that Eap acts as a strong enhancer of thiol isomerase activity. Over the last years, a strong involvement of platelet-surface thiol isomerases in platelet activation has become evident. [27] [28] [29] [30] We tested the effect of Eap on platelet function, and found that Eap induces binding of plasma proteins to platelets, platelet aggregation, and degranulation. The thiol isomerase inhibitor bacitracin and anti-protein disulfide isomerase (PDI) antibody inhibited platelet activation by Eap. Eapinduced PDI and platelet activation were completely blocked by glycosaminoglycans as well as by the hydrophobic probe bis(1-anilinonaphthalene 8-sulfonate) (bis-ANS). Because the rapidity and degree of platelet aggregation by S aureus has been shown to correlate with the severity of disseminated intravascular coagulation, 31, 32 the new findings might be important for pathophysiology.
Materials and Methods
All studies were approved by the local ethics committee. Blood was obtained with informed consent from healthy volunteers who had not taken any medication affecting platelet function for at least 2 weeks before the study. Detailed Materials and Methods are available in the online-only Data Supplement.
Statistical Analysis
The results are expressed as meanSD. Statistical significance was determined by using 1-way ANOVA followed by post hoc Bonferroni. P0.05 was regarded as significant.
Results

Platelets Adhere to Eap
Because Eap shows such a broad binding spectrum to matrix and plasma proteins, we investigated the adherence of platelets to Eap. Platelets bound to immobilized Eap under static conditions, assayed via hexosaminidase activity, as well as in whole blood under flow (2 dynes/cm 2 and 10 dynes/ cm 2 ; Figure 1A ). In some of these experiments under flow conditions (2 dynes/cm 2 ), thrombus formation was also observed ( Figure II in the online-only Data Supplement). In a control experiment without immobilized Eap, adherence of platelets was not observed ( Figure 1A ). In addition, fluorescence activated cell sorter (FACS) analysis ( Figure  1B ) as well as fluorescence microscopy ( Figure III in the online-only Data Supplement) revealed the direct binding of soluble Eap to the surface of nonpermeabilized gel-filtered platelets and the localization of Eap between platelets in microaggregates.
Shedding of glycosaminoglycans from the platelet surface by using chondroitinase ABC dramatically reduced binding of soluble Eap to platelets ( Figure 1B) .
McGavin et al 19 noticed that Eap has the tendency to selfaggregate in solution, and they speculated that this is due to a high content of hydrophobic amino acids. Therefore, we tested if these hydrophobic protein regions of Eap contribute to its binding to platelets. The compound bis-ANS binds to hydrophobic patches, and is a dye which is commonly used to locate misfolded proteins by binding to their hydrophobic regions. As shown in Figure 1B , binding of Eap to platelets was blocked by bis-ANS. The combined treatment with chondroitinase ABC and bis-ANS further reduced Eap binding ( Figure 1B ).
Eap Activates Thiol Isomerases on Platelet Surface
Eap in concentrations similar to those found in supernatants of S aureus strains 18 diminished the number of free ectosulfhydryls on platelets in a dose-dependent manner (Figure 2A ), although Eap has no cysteines itself. 33 Free sulfhydryls and thiol isomerase-catalyzed disulfide exchange on the platelet surface play a major role in platelet function. Therefore, the decrease of free exofacial thiols might reflect an interaction of Eap with platelet-surface thiol isomerases, such as PDI, endoplasmic reticulum stress protein 57 (ERp57), and ERp72.
As shown in Figure 2B , Eap (2.5-20 g/mL) potentiated the platelet-catalyzed reduction of nonfluorescent dieosin glutathione disulfide to fluorescent eosin-glutathione in a dose-dependent manner. In a control experiment without platelets, we verified that Eap alone did not reduce dieosin glutathione disulfide (data not shown). When platelets were pretreated with the inhibitory monoclonal anti-PDI antibody RL77, Eap-induced platelet surface reductase activity was significantly reduced ( Figure 2C ), and pretreatment of platelets with the membrane-impermeable thiol isomerase inhibitor bacitracin completely abolished platelet surface reductase activity ( Figure 2D) . Furthermore, the treatment of recombinant PDI, ERp57, and ERp72 with Eap resulted in an enhanced reductase activity of these enzymes ( Figure  2E ; Figure IV in the online-only Data Supplement). In addition to reduction of dieosin glutathione disulfide, Eap also potentiated the renaturation of scrambled ribonuclease by PDI and platelets (data not shown). Using ELISA technique, we were able to show that Eap bound directly to PDI, ERp57, and ERp72 ( Figure 2F ; Figure IV in the online-only Data Supplement). Binding of Eap to thiol isomerases was inhibited by heparin as well as by the hydrophobic probe bis-ANS ( Figure 2F ; Figure IV in the online-only Data Supplement).
Eap Activates Platelets
Previously, we reported that sustained binding of Fg to its integrin receptor  IIb  3 depends on free thiols and PDI-catalyzed disulfide exchange. 29 Therefore, the effect of Eap on platelet Fg binding was tested. Eap (2.5-20 g/mL) induced the binding of fluorescein isothiocyanate (FITC)-coupled Fg to resting platelets in a concentration-dependent manner ( Figure  3A ). Maximal response was observed after a minimum incubation time with Eap of 5 minutes at room temperature. Only the complete Eap protein activated human platelets, because Fg binding was not observed when recombinant single EAP domains were used ( Figure 3A ). Binding of FITC-coupled Fg was specific, because 100 excess of unlabeled Fg completely abolished binding of Fg-FITC (data not shown). Fg binding to Eap-treated platelets was temperature-dependent, with stronger platelet activation properties at 25°C than at 37°C (data not shown). Eap-induced platelet Fg binding was observed in whole blood, platelet-rich plasma, and with gel-filtered platelets, with the strongest binding found in platelet-rich plasma ( Figure 3A ). In addition, Eap treatment resulted in  IIb  3 integrin activation because binding of FITC-coupled pituitary adenylate cyclase-activating polypeptide type 1 antibody to platelets was induced by Eap, but not by the single EAP domain ( Figure 3B Eap not only induced Fg binding to platelets, but also triggered the next step of hemostasis, platelet aggregation. Primary as well as secondary aggregation of platelets and platelet shape change were observed after treatment of plateletrich plasma with Eap (3.25-7.5 g/mL) in a dose-dependent manner ( Figure 3C ).
The observation of a second aggregation wave indicated an effect of Eap on platelet granule release. Therefore, we measured P-selectin (CD62P) expression on platelets as a marker for -granule release, and found a dose-dependent increase in surface-expressed CD62P after incubation of resting platelets with Eap ( Figure 3D ). Eap-induced platelet CD62P expression was also observed in whole blood and with gel-filtered platelets (Figure VI in the online-only Data Supplement). In addition, Eap treatment increased the expression of CD63, a marker of dense body release, in a concentration-dependent manner ( Figure 3D ). Surface presentation of CD40 ligand was also observed after treatment of platelets with Eap ( Figure  3D ). In contrast, the single EAP domain did not induce the platelet surface expression of CD62P, CD63, and CD40 ligand ( Figure 3D ).
Involvement of Platelet Signaling in Activation by Eap
Eap is known to bind to a multitude of host plasma and matrix proteins including Fg, fibronectin, TSP-1, and vitronectin. [18] [19] [20] In addition, we found that Eap binds to platelets, and induces the binding of plasma proteins to platelets. Using specific inhibitors of glycoprotein IIb (GPIIb) Figure 4A ). In contrast, platelet CD62P expression was not affected by Arg-Gly-Asp-Ser peptide or abciximab ( Figure 4B ).
Next we investigated the contribution of platelet signaling to Eap-induced platelet Fg binding. Eap induced binding of a pronounced higher number of Fg molecules to platelets from citrate-anticoagulated blood than to platelets from EDTAanticoagulated blood. Only this additional binding of Fg molecules was inhibited by the synthetic prostacyclin analog iloprost ( Figure 4C ). In contrast, EDTA and iloprost inhibited Eap-induced platelets CD62P expression completely ( Figure 4D ).
Thiol-Reactive Compounds Inhibit Eap-Induced Platelet Activation
As shown in Figure 2A , the cysteine-free protein Eap diminished the number of free ectosulfhydryls on platelets. Therefore, we investigated the effect of thiol-reactive substances on Eapinduced Fg binding to platelets. The 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) and para-chloromercuri-phenylsulfonate, the 2 membrane-impermeable thiol blockers 5,5'-dithiobis-2-nitobenzoid acid (DTNB) and para-chloromercuri-phenylsulfonate were used to study the influence of ectosulfhydryls on Eapmediated Fg binding to platelets. DTNB significantly inhibited at concentrations of 2 to 7.5 mmol/L with complete blockade of Fg binding with 7.5-mmol/L DTNB ( Figure 5A ). Parachloromercuri-phenylsulfonate in concentrations of 25 to 200 mol/L worked as an inhibitor as well ( Figure 5B ). Eap-induced CD62P expression was also blocked by DTNB and para-chloromercuri-phenylsulfonate ( Figure VII in the online-only Data Supplement). In addition, total inhibition of Eap-induced Fg binding was observed after platelet treatment with 200-nM phenylarsine oxide, an inhibitor of vicinal thiols ( Figure 5C ). Furthermore, the thiol-binding fungal gliotoxin, shown to inhibit platelet activation by interaction with thiols 34 and the plant sesquiterpene lactone parthenolide (feverfew), known to interact with the sulfhydryl group of glutathione 35 blocked Eapinduced platelet Fg binding completely (data not shown).
Eap-Induced Platelet Activation Depends on Platelet-Surface Thiol Isomerases
Because Eap stimulated PDI reductase activity as well as platelet surface reductase activity, we checked if Eapinduced platelet activation depends on platelet surface PDI. Pretreatment of platelets with 10 mmol/L of bacitracin, a membrane-impermeable inhibitor of thiol isomerases, including PDI, 36 blocked Eap-induced platelet Fg binding completely ( Figure 5D ). When platelets were pretreated with the inhibitory monoclonal anti-PDI antibody RL77, Eap-induced platelet Fg binding was significantly reduced whereas control isotype IgG had no effect ( Figure 5E ). In addition, externally added soluble PDI inhibited Eap-induced platelet Fg binding in a dose-dependent manner (data not shown).
Proteoglycans and bis-ANS Inhibit Eap-Induced PDI Stimulation and Platelet Activation
In a previous study, it has been shown that binding of Eap to Fg, vitronectin, fibronectin, and intracellular adhesion molecule 1 was displaced by heparin. 22 Hence, we studied the effect of heparin and heparinoids in comparison to other anticoagulants on Eap-induced Fg binding to platelets. Eap-induced Fg binding was not observed using platelets isolated from blood anticoagulated with 5-U/mL unfractionated (UF) heparin or 20-U/mL low molecular weight heparin ( Figure 6A ). As for UF heparin and low molecular weight heparin, pretreatment of platelets with 1-U/mL danaparoid sodium and its ingredient heparan sulfate (54 g/mL) completely inhibited the effect of Eap on platelet Fg binding ( Figure 6A ). UF heparin, low molecular weight heparin, danaparoid sodium, and heparan sulfate also blocked Eap-induced platelet CD62P expression ( Figure 6A ). In addition, pretreatment of platelets with chondroitinase ABC diminished Eap-induced Fg binding to platelets as well as CD62P expression significantly ( Figure 6A ). In contrast, the synthetic pentasaccharide fondaparinux (1 g/mL) as well as the direct thrombin inhibitor hirudin (5 U/mL) had no impact on the effect of Eap on platelet Fg binding ( Figure 6A ). UF heparin also inhibited Eap-induced PDI activity as well as platelet surface reductase activity ( Figure 6B ). In addition, pretreatment of platelets with chondroitinase ABC diminished Eap-induced platelet surface reductase activity significantly ( Figure 6B) .
Furthermore, Eap-induced Fg binding was completely blocked by the hydrophobic probe bis-ANS ( Figure 6C ). Total inhibition of CD62P expression was also observed with bis-ANS ( Figure 6C ). In addition, bis-ANS inhibited Eap-induced PDI activity and platelet surface reductase activity significantly ( Figure 6D ).
Discussion
S aureus has increasingly been recognized as a cause of severe invasive illness like sepsis or IE, diseases that are accompanied by thrombotic sequelae. The ability of S aureus to interact with platelets contributes to the pathogenesis of IE. 37 The secreted S aureus adhesin Eap shows a broad repertoire of interactions with components of the host extracellular matrix. 18, 19 Here, we describe that Eap also binds to platelets, and that platelets adhere to Eap-coated surfaces under static as well as under flow conditions. Moreover, the formation of thrombi on Eap-coated surfaces was observed under flow. Binding of Eap to platelets was completely inhibited after chondroitinase ABC treatment. These data are in accordance with the previously described blocking of Eap interactions with matrix molecules by heparin, 22 and suggest an involvement of glycosaminoglycans in Eap binding to platelets.
McGavin et al 19 observed that Eap has the tendency to selfaggregate in solution, and they speculated that this is due to a high content of hydrophobic amino acids. Inhibition by bis-ANS indicates a strong contribution of hydrophobic regions in Eap binding to platelets.
Treatment of platelets with the cysteine-free protein Eap was accompanied by a decrease of free thiol groups on the platelet surface. Free ectosulfhydryls and catalyzed disulfide exchanges are strongly involved in platelet activation and aggregation. 29 A principal candidate for such catalysis is PDI, an enzyme of the ER unfolded protein response system, which has been also identified on the surface of cells including platelets. 38 Surface-located PDI is associated with a broad range of functions. On the platelet surface, PDI is implicated in integrin activation, and mediates platelet adhesion, aggregation, granule secretion as well as thrombin formation on the platelet surface. [27] [28] [29] [39] [40] [41] Besides PDI, 6 other thiol isomerases have been identified on the platelet surface so far, namely, ERp5, ERp57, ERp72, ERp44, ERp29, and TMX3. 30, 42 Like PDI, ERp5 and ERp57 are involved in platelet aggregation, integrin activation, and degranulation. 30, 43, 44 Various molecules are known, which bind to PDI and inhibit its thiol isomerase activity. Here, we report that the staphylococcal adhesin Eap potentiates platelet surface reductase activity. Because the monoclonal inhibitory anti-PDI antibody RL77 markedly inhibited Eap-potentiated platelet surface reductase activity, Eap seems to stimulate PDI reductase activity on the platelet surface. RL77 did not completely block the effect of Eap on platelet surface reductase activity, suggesting the involvement of other thiol isomerases as well. This is also supported by the fact that bacitracin, a cell-impermeable relative nonselective inhibitor of thiol isomerases, completely blocked platelet surface reductase activity.
Indeed, we observed a potentiating effect of Eap on the reductase activities of the thiol isomerases PDI, ERp57, and ERp72, indicating a general potentiation of thiol isomerase activity by Eap. Using ELISA technique, we were able to show that Eap bound directly to these thiol isomerases. Binding of Eap to thiol isomerases was inhibited by heparin as well as by bis-ANS, indicating complex formation of Eap with heparin and involvement of hydrophobic residues in thiol isomerase binding.
Besides stimulation of PDI reductase activity, we found that Eap induces platelet activation and aggregation. Eapinduced platelet Fg binding was assayed using FITC-coupled Fg. Controls with unlabeled Fg revealed specific binding of Fg-FITC to platelets. Fg binding to platelets was stimulated by Eap in a concentration-, time-, and temperature-dependent manner. Eap contains 4 to 6 tandem repeat (EAP) domains. None of the domains alone were able to induce platelet Fg binding. This result is in accordance with the observation that 1 tandem repeat domain of Eap is required for protein aggregation, bacterial adherence, and host cell invasion. 45 Increased pituitary adenylate cyclase-activating polypeptide type 1 binding revealed an activation of  IIb  3 by Eap. Based on the knowledge that sustained Fg binding to  IIb  3 depends on platelet surface PDI, 29 Eap-induced platelet Fg binding might be at least, in part, a consequence of PDI stimulation. In addition to Fg, Eap-treated platelets bound also TSP-1, fibronectin, and vitronectin. Noteworthy, TSP-1, fibronectin, and vitronectin contain thiol groups, which have been associated with their function. Furthermore, PDI catalyzes disulfide exchanges in TSP-1 and vitronectin. 46, 47 Eap also induced platelet shape change as well as primary and secondary aggregation of platelets, platelet degranulation, and CD40 ligand surface presentation. CD40 ligand-CD40 interactions have been proposed to play a pathogenic role in both the long-term atherosclerotic process and in triggering and propagation of acute coronary syndromes. 48, 49 Platelet aggregation and secretion are mediated by platelet surface PDI. 29, 39 Eap is known to bind host plasma proteins including Fg, fibronectin, and TSP-1. 18, 19 Here we show that Eap also binds to platelets, and induces binding of plasma proteins to platelets. Therefore, it was important to define the mechanism of Eap-induced plasma protein binding. Using Arg-Gly-Asp-Ser peptide and abciximab (ReoPro), we were able to show that Eap-induced binding of Fg to platelets did not only occur via Eap as a bridging molecule, but, in part, also via GPIIb/IIIa. Sustained binding of Fg to GPIIb/IIIa requires PDI-dependent activation of the receptor through inside-out signaling. 29 Therefore, platelet signaling pathways are involved in Fg binding to platelet GPIIb/IIIa. The Ca 2+ chelator EDTA and the prostacyclin analog iloprost inhibited Eap-induced platelet Fg binding only in part. In contrast, CD62P expression was completely inhibited by EDTA as well as by iloprost, showing Eap-induced granule release to be totally dependent on platelet signaling. Because CD62P expression was unaffected by ArgGly-Asp-Ser peptide and abciximab, Fg binding to GPIIb/IIIa is not required for Eap-induced -granule release, suggesting GPIIb/IIIa is not the only signaling receptor to be involved.
The importance of free thiol groups for platelet activation by Eap was confirmed by using thiol-reactive compounds. Platelet Fg binding was abolished in the presence of membrane-impermeable thiol blockers like DTNB and parachloromercuri-phenylsulfonate. These thiol blockers did not only block Fg binding, but also -granule release, suggesting a more general involvement of free thiol groups in platelet activation by Eap. The importance of thiol isomerases for Eap-induced platelet activation was confirmed by blocking of platelet activation by Eap with the membrane-impermeable thiol isomerase inhibitor bacitracin. In contrast to iloprost and EDTA, bacitracin blocked Eap-induced platelet Fg binding completely.
PDI was involved in Eap-induced platelet activation, because the inhibitory antibody anti-PDI clone RL77 significantly inhibited Eap-induced Fg binding to platelets. Addition of soluble PDI decreased Eap-induced platelet activation in a dose-dependent manner, suggesting a direct interaction of Eap with PDI and the importance of platelet-bound instead of soluble PDI for platelet activation by Eap.
We found that glycosaminoglycans, but not direct thrombin inhibitors or the pentasaccharide fondaparinux, blocked PDI stimulation by Eap as well as Eap-induced Fg binding to platelets. In addition, shedding of glycosaminoglycans from the platelet surface by chondroitinase ABC inhibited platelet activation by Eap. Therefore, binding of Eap to glycosaminoglycans is likely to contribute to adherence of S aureus to platelets and host tissue. Inhibition of Eap-induced platelet activation by UF and low molecular weight heparins as well as by the heparinoid orgaran reveals a previously unidentified additional mechanism contributing to the positive treatment effects of heparin or heparinoids against disseminated intravascular coagulation in S aureus septicemia. The heparinoid danaparoid sodium has been shown to act as an inhibitor of systemic inflammation in sepsis models. 50 The inhibition of the PDI-activating effects of secreted proteins from microorganisms might contribute to these positive effects. The results show, in addition, that preventing of disseminated intravascular coagulation by heparin or heparinoids does not solely depend on the inhibition of thrombin by heparin-antithrombin complexes.
Eap-induced PDI stimulation and platelet activation were inhibited by bis-ANS, indicating an involvement of hydrophobic residues of Eap in thiol isomerase stimulation and therefore in platelet activation. Eap has the tendency to self-aggregate in solution and a high content of hydrophobic amino acids. 19 These are characteristics, which Eap shares with amyloids and other misfolded proteins. 51 Herczenik et al 52 found that misfolded proteins activate platelets. Therefore, the mimicry of the structure of a misfolded protein might be an explanation for Eap-induced thiol isomerase stimulation and platelet activation. This suggestion is strengthened by our findings that Eap binds directly to the chaperone glucose-regulated protein 78, and increases the fluorescence of bis-ANS, which is used for the detection of misfolded proteins ( Figure VIII in the online-only Data Supplement).
We recently reported that -defensins, which are secreted by neutrophils after contact with microorganisms, activate platelets by the formation of amyloid-like proteins. 53 Whether Eap activates platelets in a similar way and acts in concert with -defensins is the target of further studies.
Recently, another protein secreted by S aureus, the staphylococcal superantigen-like protein 5 has been shown to bind to platelets and activate them in a GPVI and GPIb-dependent mechanism.
54, 55 Binding of superantigen-like protein 5 to platelets depended on sialylated glycans. 55 But in contrast to Eap-induced platelet activation, platelet activation by superantigen-like protein 5 was absent in the presence of plasma or in whole blood. 54 Hu et al 55 suggested that in vivo platelets might need prior stimulation before superantigenlike protein 5 can exert its activity.
Furthermore, several surface proteins of S aureus have been shown to induce platelet activation and aggregation, including the clumping factors ClfA and ClfB, and the fibronectin-binding proteins FnBPA and FnBPB. 12, 13 How these proteins work in concert with Eap in platelet activation during S aureus blood stream infection has to be the subject for further investigations.
In conclusion, we showed that Eap in concentrations similar to those found in supernatants of S aureus strains 18 stimulate platelet-surface thiol isomerases, and exhibit prothrombotic properties by aggregating human blood platelets. The activation of platelets by potentiating the activity of surface thiol isomerases represents an additional and yet unknown mechanism of platelet stimulation by S aureus. The hydrophobic structure might be the reason for Eapinduced thiol isomerase stimulation and consequential platelet activation. Further investigations are necessary to decipher this new thiol isomerase-dependent mechanism of platelet activation completely. The prothrombotic activity of Eap might contribute to thrombus formation in IE and S aureus septicemia. The thiol isomerase stimulatory and prothrombotic feature presented by a secreted protein from a microorganism is probably not restricted to S aureus and Eap. Because many microorganisms have a coat of amyloidogenic proteins, it is likely that the observed mechanism is a more general one. 
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